These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 19449121)
1. Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. Lo KL; Chan MC; Wong A; Hou SM; Ng CF Int Urol Nephrol; 2010 Mar; 42(1):7-12. PubMed ID: 19449121 [TBL] [Abstract][Full Text] [Related]
2. Prostate size influences the outcome after presenting with acute urinary retention. McNeill AS; Rizvi S; Byrne DJ BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112 [TBL] [Abstract][Full Text] [Related]
3. Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis. Bansal A; Arora A Neurourol Urodyn; 2017 Sep; 36(7):1757-1762. PubMed ID: 28101889 [TBL] [Abstract][Full Text] [Related]
4. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Alan McNeill S Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678 [TBL] [Abstract][Full Text] [Related]
5. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. Desgrandchamps F; De La Taille A; Doublet JD; BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763 [TBL] [Abstract][Full Text] [Related]
6. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K; BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624 [TBL] [Abstract][Full Text] [Related]
7. Does acute urinary retention respond to alpha-blockers alone? McNeill SA Eur Urol; 2001 Mar; 39 Suppl 6():7-12. PubMed ID: 11306895 [TBL] [Abstract][Full Text] [Related]
8. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358 [TBL] [Abstract][Full Text] [Related]
9. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis. Morlock R; Goodwin B; Gomez Rey G; Eaddy M Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026 [TBL] [Abstract][Full Text] [Related]
10. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. McNeill SA; Hargreave TB; Roehrborn CG; Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868 [TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of management of patients presenting with acute urinary retention due to benign prostatic hyperplasia: a hospital based study. Pandit RK; Agrawal CS; Chalise PR; Sapkota G Kathmandu Univ Med J (KUMJ); 2008; 6(24):448-52. PubMed ID: 19483424 [TBL] [Abstract][Full Text] [Related]
12. The Reten-World survey of the management of acute urinary retention: preliminary results. Emberton M; Fitzpatrick JM BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683 [TBL] [Abstract][Full Text] [Related]
13. Management outcome of acute urinary retention: model of prediction. Daly P; Connolly S; Rogers E; Sweeney P Urol Int; 2009; 83(1):39-43. PubMed ID: 19641357 [TBL] [Abstract][Full Text] [Related]
14. Long-term results of medical treatment in benign prostatic hyperplasia. Kim CI; Chang HS; Kim BK; Park CH Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071 [TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia. Zhengyong Y; Changxiao H; Shibing Y; Caiwen W Scand J Urol; 2014 Aug; 48(4):400-4. PubMed ID: 24697345 [TBL] [Abstract][Full Text] [Related]
16. [Clinical outcomes after combined therapy with dutasteride in patients with unsuccessful trial without catheter after treatment with an alpha1-adrenergic receptor blocker monotherapy for acute urinary retention caused by prostatic hyperplasia]. Inahara M; Sugiura M; Kaga K; Hou K; Araki K; Masuda H; Kojima S; Naya Y Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):190-5. PubMed ID: 25757349 [TBL] [Abstract][Full Text] [Related]
17. [Alpha-adrenergic blockers as a support in the treatment of acute urinary retention]. Altarac S Lijec Vjesn; 2006; 128(7-8):233-7. PubMed ID: 17087140 [TBL] [Abstract][Full Text] [Related]
18. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia. Bhomi KK; Bhattachan CL Nepal Med Coll J; 2011 Sep; 13(3):178-81. PubMed ID: 22808810 [TBL] [Abstract][Full Text] [Related]
19. Saline bladder infusion vs standard catheter removal in patients with acute urinary retention related to benign prostatic hyperplasia: The BLAPERF Study. Corral R; Boissier R; Depaquit TL; Gondran-Tellier B; Bastide C; Lechevallier E; Baboudjian M Prog Urol; 2023 May; 33(6):319-324. PubMed ID: 36842924 [TBL] [Abstract][Full Text] [Related]
20. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Logan YT; Belgeri MT Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]